ARNA Related Downgrades
-
Brean Capital Downgrades Vivus (VVUS) to Sell, Low Qsymia Coverage Means Low Sales
-
BMO Capital Downgrades Arena Pharma (ARNA) to Market Perform Ahead of PDUFA
-
Arena (ARNA) Shares Sink as Piper Jaffray Downgrade Weighs
-
Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral
-
Arena Pharma (ARNA) Shares Downgraded at WBB Securities, CRT Capital This Morning
-
Davenport Downgrades Arena Pharmaceuticals (ARNA) to Neutral; PT Suspended
-
Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral, Price Target Slashed to $1.50
-
Analyst Cuts Arena (ARNA) to Sell as Lorcaserin 'Cancer Risk Unlikely to be Ruled Out'
-
Cowen Downgrades Arena Pharma (ARNA) Ahead of Tomorrow's FDA Panel Meeting
-
Jefferies, BMO Issue Afternoon Downgrades on Arena Pharma (ARNA)
-
Barclays Downgrades Arena Pharmaceuticals (ARNA) to Underweight; EMDAC Risk-reward Unfavorable
-
Analyst Round-Up Arena Pharma (ARNA): Downgraded at Barclays, Oppenheimer, Defended by Piper Jaffray
-
Hapoalim Securities Downgrades Arena Pharma (ARNA) to Sell
-
Arena Pharma (ARNA) Shares Downgraded at Hapoalim, Leerink; Stock Giving Up Gains
-
JP Morgan Downgrades Arena Pharmaceuticals (ARNA) to Neutral
-
Rodman & Renshaw Downgrades Arena Pharmaceuticals (ARNA) to Market Underperform
-
J.P. Morgan on Biotechnology and Drugs Stocks; Upgrades ARNA, Cuts VVUS
-
Leerink Swann Downgrades Arena Pharmaceuticals (ARNA) to Market Perform
-
Rodman & Renshaw Cuts Arena Pharma (ARNA) to Underperform
-
Rodman and Renshaw Downgrades Arena Pharma (ARNA) to Market Perform
-
Needham Downgrades Arena Pharmaceuticals (ARNA) to Hold
-
Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks
-
UBS Downgrades Arena Pharmaceuticals (ARNA) to Neutral
-
AG Edwards downgrades Arena Pharma (ARNA) to Hold
Back to ARNA Stock Lookup
